<p>Immunome（納斯達克：IMNM - 獲取免費報告）在週一發佈給客户和投資者的研究報告中被高盛集團的股票研究人員升級為 “強力買入” 評級，Zacks.com 報道。</p>
<ul>
<li>3 只小盤股具有巨大的增長潛力</li>
</ul>
<p>其他幾家研究公司也最近對 IMNM 發表了看法。Guggenheim 在 8 月 25 日的研究報告中重申了 “買入” 評級，並對 Immunome 的股票設定了 25.00 美元的目標價。摩根大通將 Immunome 的股票目標價從 23.00 美元下調至 22.00 美元，並在 8 月 7 日的研究報告中為該公司設定了 “增持” 評級。Wedbush 在 9 月 18 日的研究報告中重申了 “跑贏大盤” 評級，並對 Immunome 的股票設定了 21.00 美元的目標價。Evercore ISI 在 8 月 22 日的研究報告中開始覆蓋 Immunome 的股票，給予 “跑贏大盤” 評級，並設定了 18.00 美元的目標價。最後，Craig Hallum 在 9 月 5 日的研究報告中開始覆蓋 Immunome 的股票，給予 “買入” 評級，並設定了 26.00 美元的目標價。一位投資分析師對該股票給予了強力買入評級，九位分析師對該公司的股票給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “買入”，共識目標價為 23.20 美元。</p>
<p><strong>獲取我們關於 Immunome 的最新股票報告</strong></p>
<h2>Immunome 股價上漲 4.0%</h2>
<p>IMNM 週一開盤價為 9.77 美元。該公司的市值為 8.5038 億美元，市盈率為-3.17，貝塔值為 1.92。Immunome 的 1 年最低價為 5.15 美元，1 年最高價為 15.40 美元。該公司的 50 日移動平均價格為 10.03 美元，200 日移動平均價格為 8.84 美元。</p>
<p>Immunome（納斯達克：IMNM - 獲取免費報告）最近在 8 月 6 日發佈了季度財報。該公司報告季度每股收益為（0.50 美元），超出市場共識預期的（0.52 美元）0.02 美元。該公司在本季度的收入為 402 萬美元，而分析師預期為 103 萬美元。Immunome 的淨利潤率為-1687.08%，股本回報率為-76.10%。平均而言，研究分析師預測 Immunome 在當前年度的每股收益為-2.21 美元。</p>
<h2>Immunome 的機構交易</h2>
<p>一些對沖基金和其他機構投資者最近對該公司的持倉進行了調整。T. Rowe Price Investment Management Inc.在第一季度將其在 Immunome 的持股增加了 37.4%。T. Rowe Price Investment Management Inc.目前擁有 7554594 股該公司的股票，價值 50843000 美元，此前在上個季度購買了 2054640 股。Redmile Group LLC 在第一季度將其在 Immunome 的持股增加了 11.0%。Redmile Group LLC 目前擁有 5361187 股該公司的股票，價值 36081000 美元，此前在上個季度購買了 533161 股。Vanguard Group Inc.在第一季度將其在 Immunome 的持股增加了 43.4%。Vanguard Group Inc.目前擁有 4307191 股該公司的股票，價值 28987000 美元，此前在上個季度購買了 1303753 股。EcoR1 Capital LLC 在第一季度將其在 Immunome 的持股增加了 5.2%。EcoR1 Capital LLC 目前擁有 4079415 股該公司的股票，價值 27454000 美元，此前在上個季度購買了 200000 股。最後，Primecap Management Co. CA 在第一季度將其在 Immunome 的持股增加了 1115.7%。Primecap Management Co. CA 目前擁有 3413700 股該公司的股票，價值 22974000 美元，此前在上個季度購買了 3132900 股。44.58% 的股票目前由機構投資者和對沖基金持有。</p>
<h2>關於 Immunome</h2>
<p>（獲取免費報告）</p>
<p>Immunome, Inc.是一家生物技術公司，開發靶向癌症療法。該公司的臨牀資產包括 AL102，一種正在評估的伽馬分泌酶抑制劑，目前正在進行針對纖維瘤的三期試驗；前臨牀資產包括 IM-1021，一種受體酪氨酸激酶樣孤兒受體 1 和抗體藥物偶聯物，以及 IM-3050，一種針對成纖維細胞活化蛋白的放射性配體療法；以及 IM-4320，一種抗 IL-38 免疫療法候選藥物。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Immunome 更好</li>
<li>什麼是盈利驚喜？</li>
<li>疲軟的美元如何推動這些全球股票的飆升</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>3 只在經濟低迷時表現良好的股票</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>3 只被低估的自動化股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Immunome 嗎？</h2>
<p>在你考慮 Immunome 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Immunome 並不在名單上。</p>
<p>雖然 Immunome 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMNM

<p>高盛集團在最近的一份研究報告中將 Immunome（NASDAQ:IMNM）的評級上調至 “強烈買入”。包括古根海姆和摩根大通在內的其他公司也對該股票給予了積極的評級和價格目標。Immunome 的股票開盤價為 9.77 美元，市值為 8.5038 億美元。該公司報告的季度收益超出預期，收入大幅超過預期。機構投資者已增加對 Immunome 的持股，該公司專注於開發靶向癌症療法</p>

<p>Immunome (NASDAQ:IMNM - Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group to a &#34;strong-buy&#34; rating in a research report issued to clients and investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Immunome（納斯達克：IMNM - 獲取免費報告）在週一發佈給客户和投資者的研究報告中被高盛集團的股票研究人員升級為 “強力買入” 評級，Zacks.com 報道。</p>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盤股具有巨大的增長潛力</li>
</ul>
</div><p>Several other research firms have also recently weighed in on IMNM. Guggenheim restated a &#34;buy&#34; rating and issued a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. JPMorgan Chase &amp; Co. lowered their price objective on shares of Immunome from $23.00 to $22.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, August 7th. Wedbush restated an &#34;outperform&#34; rating and issued a $21.00 price objective on shares of Immunome in a research report on Thursday, September 18th. Evercore ISI began coverage on shares of Immunome in a research report on Friday, August 22nd. They issued an &#34;outperform&#34; rating and a $18.00 price objective for the company. Finally, Craig Hallum began coverage on shares of Immunome in a research note on Friday, September 5th. They issued a &#34;buy&#34; rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $23.20.</p>
<div class="lb-trans"><p>其他幾家研究公司也最近對 IMNM 發表了看法。Guggenheim 在 8 月 25 日的研究報告中重申了 “買入” 評級，並對 Immunome 的股票設定了 25.00 美元的目標價。摩根大通將 Immunome 的股票目標價從 23.00 美元下調至 22.00 美元，並在 8 月 7 日的研究報告中為該公司設定了 “增持” 評級。Wedbush 在 9 月 18 日的研究報告中重申了 “跑贏大盤” 評級，並對 Immunome 的股票設定了 21.00 美元的目標價。Evercore ISI 在 8 月 22 日的研究報告中開始覆蓋 Immunome 的股票，給予 “跑贏大盤” 評級，並設定了 18.00 美元的目標價。最後，Craig Hallum 在 9 月 5 日的研究報告中開始覆蓋 Immunome 的股票，給予 “買入” 評級，並設定了 26.00 美元的目標價。一位投資分析師對該股票給予了強力買入評級，九位分析師對該公司的股票給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “買入”，共識目標價為 23.20 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Immunome</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Immunome 的最新股票報告</strong></p>
</div><h2>Immunome Trading Up 4.0%</h2>
<div class="lb-trans"><h2>Immunome 股價上漲 4.0%</h2>
</div><p>IMNM opened at $9.77 on Monday. The stock has a market capitalization of $850.38 million, a PE ratio of -3.17 and a beta of 1.92. Immunome has a 1-year low of $5.15 and a 1-year high of $15.40. The firm has a 50-day moving average price of $10.03 and a two-hundred day moving average price of $8.84.</p>
<div class="lb-trans"><p>IMNM 週一開盤價為 9.77 美元。該公司的市值為 8.5038 億美元，市盈率為-3.17，貝塔值為 1.92。Immunome 的 1 年最低價為 5.15 美元，1 年最高價為 15.40 美元。該公司的 50 日移動平均價格為 10.03 美元，200 日移動平均價格為 8.84 美元。</p>
</div><p>Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. On average, research analysts predict that Immunome will post -2.21 EPS for the current year.</p>
<div class="lb-trans"><p>Immunome（納斯達克：IMNM - 獲取免費報告）最近在 8 月 6 日發佈了季度財報。該公司報告季度每股收益為（0.50 美元），超出市場共識預期的（0.52 美元）0.02 美元。該公司在本季度的收入為 402 萬美元，而分析師預期為 103 萬美元。Immunome 的淨利潤率為-1687.08%，股本回報率為-76.10%。平均而言，研究分析師預測 Immunome 在當前年度的每股收益為-2.21 美元。</p>
</div><h2>Institutional Trading of Immunome</h2>
<div class="lb-trans"><h2>Immunome 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immunome by 37.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock valued at $50,843,000 after purchasing an additional 2,054,640 shares during the last quarter. Redmile Group LLC raised its holdings in shares of Immunome by 11.0% in the first quarter. Redmile Group LLC now owns 5,361,187 shares of the company's stock valued at $36,081,000 after purchasing an additional 533,161 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Immunome by 43.4% in the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company's stock valued at $28,987,000 after purchasing an additional 1,303,753 shares during the last quarter. EcoR1 Capital LLC increased its holdings in Immunome by 5.2% during the first quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company's stock worth $27,454,000 after buying an additional 200,000 shares during the last quarter. Finally, Primecap Management Co. CA increased its holdings in Immunome by 1,115.7% during the first quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company's stock worth $22,974,000 after buying an additional 3,132,900 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對該公司的持倉進行了調整。T. Rowe Price Investment Management Inc.在第一季度將其在 Immunome 的持股增加了 37.4%。T. Rowe Price Investment Management Inc.目前擁有 7554594 股該公司的股票，價值 50843000 美元，此前在上個季度購買了 2054640 股。Redmile Group LLC 在第一季度將其在 Immunome 的持股增加了 11.0%。Redmile Group LLC 目前擁有 5361187 股該公司的股票，價值 36081000 美元，此前在上個季度購買了 533161 股。Vanguard Group Inc.在第一季度將其在 Immunome 的持股增加了 43.4%。Vanguard Group Inc.目前擁有 4307191 股該公司的股票，價值 28987000 美元，此前在上個季度購買了 1303753 股。EcoR1 Capital LLC 在第一季度將其在 Immunome 的持股增加了 5.2%。EcoR1 Capital LLC 目前擁有 4079415 股該公司的股票，價值 27454000 美元，此前在上個季度購買了 200000 股。最後，Primecap Management Co. CA 在第一季度將其在 Immunome 的持股增加了 1115.7%。Primecap Management Co. CA 目前擁有 3413700 股該公司的股票，價值 22974000 美元，此前在上個季度購買了 3132900 股。44.58% 的股票目前由機構投資者和對沖基金持有。</p>
</div><h2>About Immunome</h2>
<div class="lb-trans"><h2>關於 Immunome</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc.是一家生物技術公司，開發靶向癌症療法。該公司的臨牀資產包括 AL102，一種正在評估的伽馬分泌酶抑制劑，目前正在進行針對纖維瘤的三期試驗；前臨牀資產包括 IM-1021，一種受體酪氨酸激酶樣孤兒受體 1 和抗體藥物偶聯物，以及 IM-3050，一種針對成纖維細胞活化蛋白的放射性配體療法；以及 IM-4320，一種抗 IL-38 免疫療法候選藥物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>What is an Earnings Surprise?</li>
<li>How The Weak Dollar Is Fueling These Global Stock Surges</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>3 Recession-Ready Stocks That Thrive When the Economy Sputters</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>3 Automation-Focused Stocks Flying Under the Radar</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Immunome 更好</li>
<li>什麼是盈利驚喜？</li>
<li>疲軟的美元如何推動這些全球股票的飆升</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>3 只在經濟低迷時表現良好的股票</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>3 只被低估的自動化股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=IMNM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Immunome 嗎？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Immunome 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Immunome 並不在名單上。</p>
</div><p>While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immunome 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Immunome（納斯達克股票代碼：IMNM）被高盛集團升級為 “強力買入” 評級